RingConn (Gen 2 / Gen 3) vs Withings ScanWatch in 2026

RingConn (Gen 2 / Gen 3)

RingConn (the Gen 2 at about $279, plus the Gen 2 Air and a Gen 3 arriving late May 2026; from RingConn, Shenzhen) is the subscription-free archetype of the biometric ring sub-cohort: all standard features are free for life, the core positioning against Oura's required membership and Whoop's subscription-only model. Its sensors (PPG, skin temperature, SpO2, accelerometer) drive sleep, heart rate and HRV, and a deep-learning sleep-apnea / AHI screening feature, with 10-to-12-day battery (the charging case extends to about 150 days).

The verified-vs-claimed throughline: the sleep-apnea / AHI feature is a company-claimed screening capability (RingConn cites about 90.7% accuracy) that is NOT FDA-cleared. RingConn's own materials say it is 'actively pursuing clearance' and 'not intended to diagnose'; DEPLOY records the AHI claim as claimed, not cleared, the direct counterpoint to the genuinely-cleared Happy Ring in the same form factor.

On the patent front, RingConn settled and licensed cleanly in the smart-ring ITC litigation; it was not import-banned, unlike Ultrahuman. Price is $279, subscription-free.

Withings ScanWatch

The Withings ScanWatch (the ScanWatch 2 at about $349 and the ScanWatch Nova, including the Nova Brilliant at about $600, November 2024; from Withings, founded 2008 in France and independent since buying itself back from Nokia in 2018) is the hybrid-analog entry of the biometric cohort: a conventional analog watch dial paired with medical sensors (optical PPG, electrical ECG, SpO2, and TempTech24/7 continuous temperature) and about 30-day battery. Its cleared features include ECG (for AFib, sinus rhythm, and high heart rate, cleared 2021, with an OTC ECG clearance in 2025), SpO2 with breathing-disturbance detection, and temperature trends, with an optional Withings+ subscription (~$9.95/month).

It carries substantial peer-reviewed cardiologist validation for the size of the company. Cap-flag: as a French maker it is cleared in both the EU and the US, with different specific indications by region.